Trials / Completed
CompletedNCT03362879
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
COSMOS - COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 412 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
Detailed description
Participants with advanced Parkinson's Disease who have been prescribed LCIG for at least 12 months will be entered into the study cohort. Clinical data will be collected by retrospective review of the participant's medical records as well as a single study visit for current data. Treatment of the participants and follow up will be according to the physician's judgment, regional regulations and the product monograph.
Conditions
Timeline
- Start date
- 2017-12-14
- Primary completion
- 2018-12-17
- Completion
- 2018-12-17
- First posted
- 2017-12-05
- Last updated
- 2020-01-06
- Results posted
- 2020-01-06
Locations
30 sites across 11 countries: Austria, Canada, Croatia, Czechia, Greece, Hungary, Ireland, Israel, Romania, Spain, Sweden
Source: ClinicalTrials.gov record NCT03362879. Inclusion in this directory is not an endorsement.